Combined chronic treatment with citalopram and lithium does not modify the regional neurochemistry of nitric oxide in rat brain

Journal of Physiology and Pharmacology

Volumn 55, Issue 3, 2004, Pages 575-586

  Wegener, Gregers ^a   Bandpey, Z ^a   Heiberg, I L ^a   Volke, V ^b   Trabace, L ^c   Rosenberg, R ^a   Harvey, B H ^d  

^a AARHUS UNIVERSITY   (Denmark)

^b UNIVERSITY OF TARTU   (Estonia)

^c UNIVERSITY OF FOGGIA   (Italy)

^d NORTH WEST UNIVERSITY   (South Africa)

Author keywords

Augmentation strategy; Citalopram; Lithium; Nitric oxide

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; CITRULLINE; LITHIUM; NITRIC OXIDE;

ACUTE DRUG ADMINISTRATION; ANIMAL TISSUE; ARTICLE; BRAIN; CEREBELLUM; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENTIATION; ENZYME ACTIVITY; EX VIVO STUDY; FRONTAL CORTEX; HIPPOCAMPUS; IN VITRO STUDY; NEUROCHEMISTRY; NONHUMAN; PSYCHOPHARMACOTHERAPY; RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BRAIN CHEMISTRY; CEREBELLUM; CITALOPRAM; DRUG COMBINATIONS; FRONTAL LOBE; HIPPOCAMPUS; LITHIUM; MALE; NITRIC OXIDE SYNTHASE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 4844225533     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Katona CL. Lithium augmentation in refractory depression. Psychiatr Dev 1988; 6(2):153-171.
2. Rouillon F, Gorwood P. The use of lithium to augment antidepressant medication. J Clin Psychiatry 1998; 59S5:32-39.
3. Bauer M, Dopfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 1999; 19(5):427-434.
4. Jope RS, Williams MB. Lithium and brain signal transduction systems. Biochem Pharmacol 1994; 1994 Feb 9; 47:3):429-41.
5. Manji HK, Chen G, Shimon H, Hsiao JK, Potter WZ, Belmaker RH. Guanine nucleotide-binding proteins in bipolar affective disorder. Effects of long-term lithium treatment. Arch Gen Psychiatry 1995; 52:135-144.
6. Harvey BH. The neurobiology and pharmacology of depression. A comparative overview of serotonin selective antidepressants. S Afr Med J 1997; 87(4 Suppl):540-50, 552.
7. Wegener G, Bandpey Z, Heiberg IL, Mork A, Rosenberg R. Increased extracellular serotonin level in rat hippocampus induced by chronic citalopram is augmented by subchronic lithium: neurochemical and behavioural studies in the rat. Psychopharmacol (Berl) 2003; 166(2):188-194.
8. Bagetta G, Corasaniti MT, Melino G, Paoletti AM, Finazzi-Agro A, Nistico G. Lithium and tacrine increase the expression of nitric oxide synthase mRNA in the hippocampus of rat. Biochem Biophys Res Commun 1993; 197(3):1132-1139.
9. Bagetta G, Rodino P, Paoletti AM, Arabia A, Massoud R, Nistico G. Systemic administration of lithium chloride and tacrine but not kainic acid augments citrulline content of rat brain. Eur J Pharmacol 1995; 294(1):341-344.
10. Harvey B, Carstens M, Taljaard J. Lithium Modulation of Cortical Cyclic-Nucleotides - Evidence for the Yin-Yang Hypothesis. European Journal of Pharmacology 1990; 175(2):129-136.
11. Harvey BH, Taljaard J. Nitric Oxide and Cyclooxygenase-Derived Free Radicals in the Therapeutic and Toxic Effects of Lithium. Lithium 1994; 5:67-72.
12. Miller KJ, Hoffman BJ. Adenosine A3 receptors regulate serotonin transport via nitric oxide and cGMP. J Biol Chem 1994; 269(44):27351-27356.
13. Wegener G, Volke V, Rosenberg R. Endogenous Nitric Oxide decreases Hippocampal levels of Serotonin and Dopamine in vivo. Br J Pharmacol 2000; 130(3):575-580.
14. Baranano DE, Ferris CD, Snyder SH. Atypical neural messengers. Trends Neurosci 2001; 24(2):99-106.
15. Garthwaite J, Charles SL, Chess-Williams R. Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature 1988; 336(6197):385-388.
16. Narsapur SL, Naylor GJ. Methylene blue. A possible treatment for manic depressive psychosis. J Affect Disord 1983; 5(2):155-161.
17. Naylor GJ, Smith AH, Connelly P. A controlled trial of methylene blue in severe depressive illness. Biol Psychiatry 1987; 22(5):657-659.
18. Dzoljic E, De Vries R, Dzoljic MR. New and potent inhibitors of nitric oxide synthase reduce motor activity in mice. Behav Brain Res 1997; 87(2):209-212.
19. Holscher C. Nitric oxide, the enigmatic neuronal messenger: its role in synaptic plasticity [see comments]. Trends Neurosci 1997; 20(7):298-303.
20. Bernstein HG, Stanarius A, Baumann B, Henning H, Krell D, Danos P et al. Nitric oxide synthase-containing neurons in the human hypothalamus: reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics. Neuroscience 1998; 83(3):867-875.
21. Suzuki E, Yagi G, Nakaki T, Kanba S, Asai M. Elevated plasma nitrate levels in depressive states. J Affect Disord 2001; 63(1-3):221-224.
22. Harkin AJ, Bruce KH, Craft B, Paul IA. Nitric oxide synthase inhibitors have antidepressant-like properties in mice. I. Acute treatments are active in the forced swim test. Eur J Pharmacol 1999; 372(3):207-213.
23. Volke V, Wegener G, Bourin M, Vasar E. Antidepressant- and anxiolytic-like effects of selective neuronal NOS inhibitor 1-(2- trifluoromethylphenyl)-imidazole in mice. Behav Brain Res 2003; 140(1-2):141-147.
24. Segovia G, Porras A, Mora F. Effects of a nitric oxide donor on glutamate and GABA release in striatum and hippocampus of the conscious rat. Neurorep 1994; 5(15):1937-1940.
25. Trabace L, Kendrick KM. Nitric oxide can differentially modulate striatal neurotransmitter concentrations via soluble guanylate cyclase and peroxynitrite formation. J Neurochem 2000; 75(4):1664-1674.
26. Finkel MS, Laghrissi-Thode F, Pollock BG, Rong J. Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull 1996; 32(4):653-658.
27. Wegener G, Volke V, Harvey BH, Rosenberg R. Local, but not systemic, administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity. Brain Res 2003; 959(1):128-134.
28. Jopek R, Kata M, Nowak G. The activity of rat brain nitric oxide synthase following chronic antidepressant treatment. Acta Pol Pharm 1999; 56(4):307-310.
29. Volke V, Soosaar A, Koks S, Vasar E, Mannisto PT. L-arginine abolishes the anxiolytic-like effect of diazepam in the elevated plus-maze test in rats. Eur J Pharmacol 1998; 351(3):287-290.
30. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein Measurement with the Folin phenyl reagent. J Biol Chem 1951; 193:263-271.
31. Bagetta G, Massoud R, Rodino P, Federici G, Nistico G. Systemic administration of lithium chloride and tacrine increases nitric oxide synthase activity in the hippocampus of rats. Eur J Pharmacol 1993; 237(1):61-64.
32. Harvey BH, Carstens ME, Taljaard JJ. Evidence that lithium induces a glutamatergic: nitric oxide-mediated response in rat brain. Neurochem Res 1994; 19(4):469-474.
33. Nonaka S, Hough CJ, Chuang DM. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci U S A 1998; 95(5):2642-2647.
34. Dixon JF, Hokin LE. Lithium acutely inhibits and chronically up-regulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex. PNAS 1998; 95(14):8363-8368.
35. Nonaka S, Chuang DM. Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neurorep 1998; 9(9):2081-2084.
36. Harvey BH, McEwen BS, Stein DJ. Neurobiology of antidepressant withdrawal: implications for the longitudinal outcome of depression. Biol Psychiatry 2003; 54(10):1105-1117.
37. Skolnick P. Antidepressants for the new millennium. Eur J Pharmacol 1999; 375(1-3):31-40.
38. Stewart CA, Reid IC. Antidepressant mechanisms: functional and molecular correlates of excitatory amino acid neurotransmission. Mol Psychiatry 2002; 7 Suppl 1:S15-S22.
39. Denninger JW, Marietta MA. Guanylate cyclase and the .NO/cGMP signaling pathway. Biochim Biophys Acta 1999; 1411(2-3):334-350.
40. Belmaker RH, Kon M, Ebstein RP, Dasberg H. Partial inhibition by lithium of the epinephrine-stimulated rise in plasma cyclic GMP in humans. Biol Psychiatry 1980; 15(1):3-8.
41. Kanba S, Pfenning M, Kanba KS, Richelson E. Lithium ions have a potent and selective inhibitory effect on cyclic GMP formation stimulated by neurotensin, angiotensin II and bradykinin. Eur J Pharmacol 1986; 126(1-2):111-116.
42. Kanba S, Yagi G, Nakaki T, Kato R, Richelson E. Potentiation by a sodium channel activator of effects of lithium ion on cyclic AMP, cyclic GMP and inositol phosphates. Neuropharmacol 1991; 30(5):497-500.
43. Schubert T, Stoll L, Muller WE. Therapeutic concentrations of lithium and carbamazepine inhibit cGMP accumulation in human lymphocytes. A clinical model for a possible common mechanism of action? Psychopharmacol (Berl) 1991; 104(1):45-50.
44. Zatz M. Low concentrations of lithium inhibit the synthesis of cyclic AMP and cyclic GMP in the rat pineal gland. J Neurochem 1979; 32(4):1315-1321.
45. Guevara-Guzman R, Emson PC, Kendrick KM. Modulation of in vivo striatal transmitter release by nitric oxide and cyclic GMP. J Neurochem 1994; 62(2):807-810.
46. Muraki I, Inoue T, Hashimoto S, Izumi T, Ito K, Koyama T. Effect of subchronic lithium treatment on citalopram-induced increases in extracellular concentrations of serotonin in the medial prefrontal cortex. J Neurochem 2001; 76(2):490-497.
47. Stryjer R, Strous RD, Shaked G, Bar F, Feldman B, Kotler M et al. Amantadine as augmentation therapy in the management of treatment-resistant depression. Int Clin Psychopharmacol 2003; 18(2):93-96.
48. Tagliaferro P, Ramos AJ, Lopez-Costa JJ, Lopez EM, Saavedra JP, Brusco A. Increased nitric oxide synthase activity in a model of serotonin depletion. Brain Res Bull 2001; 54(2):199-205.
49. Di Cara B, Dusticier N, Forni C, Lievens JC, Daszuta A. Serotonin depletion produces long lasting increase in striatal glutamatergic transmission. J Neurochem 2001; 78(2):240-248.
50. Harrison PJ. The neuropathology of primary mood disorder. Brain 2002; 125(Pt 7):1428-1449.
51. Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med 2001; 7(5):541-547.
52. Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 2000; 57(10):925-935.
53. th 2004, DOI: 10.1007/s00213-004-1836-4.
54. Contestabile A. Roles of NMDA receptor activity and nitric oxide production in brain development. Brain Res Rev 2000; 32(2-3):476-509.
55. Jope RS, Song L, Kolasa K. Inositol trisphosphate, cyclic AMP, and cyclic GMP in rat brain regions after lithium and seizures. Biol Psychiatry 1992; 31(5):505-514.